A Randomized, Clinical Study to evaluate the Efficacy and Safety of Safoof-i-Ushba and Roghan-i-Banafsha in Taqashshur al-Jild (Psoriasis)

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Efficacy and Safety of Safoof-i-Ushba and Roghan-i-Banafsha in the Management of Taqashshur al-Jild (Psoriasis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050418

Enrollment

Registered

2023-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L408- Other psoriasis

Interventions

Intervention1: Safoof-i-Ushba and Roghan-i-Banafsha: Dosage Form: Safoof(powder) and Roghan(oil) Dose: 6gm of Powder twice daily and roghan for LA Duration: 12 weeks Route of Administration: Oral and

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient clinically stable. 2. Patient with clinically diagnosed Taqashshur al-jild (psoriasis) of plaque type. 3. Psoriasis area severity index (PASI) >=10%

Exclusion criteria

Exclusion criteria: 1. Participants aged 60years 2. Known cases of significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc. 3. Erythrodermic psoriasis. 4. Pregnancy and Lactation. 5. Patient not willing to attend treatment regularly.

Design outcomes

Primary

Measure	Time frame
1. Reduction in Psoriasis Area Severity Index (PASI) 2. Improvement in Investigators Global Assessment (IGA) 3. Improvement in Patientâ??s Global Assessment (PGA) on VASTimepoint: 12 weeks	—

Secondary

Measure	Time frame
Systemic Safety AssessmentTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactAbdur Rahman Khan

National Research Institute of Unani Medicine for Skin Disorders

aarzu763@gmail.com8574664018

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026